Retrospective validation of the postnatal Growth and Retinopathy of Prematurity (G-ROP) criteria in a Swiss cohort.


Journal

BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802

Informations de publication

Date de publication:
10 Jan 2022
Historique:
received: 23 07 2021
accepted: 20 12 2021
entrez: 11 1 2022
pubmed: 12 1 2022
medline: 13 1 2022
Statut: epublish

Résumé

Currently used screening criteria for retinopathy of prematurity (ROP) show high sensitivity for predicting treatment-requiring ROP but low specificity; over 90% of examined infants do not develop ROP that requires treatment (type 1 ROP). A novel weight gain-based prediction model was developed by the G-ROP study group to increase the specificity of the screening criteria and keep the number of ophthalmic examinations as low as possible. This retrospective cohort study aimed to externally validate the G-ROP screening criteria in a Swiss cohort. Data from 645 preterm infants in ROP screening at Inselspital Bern between January 2015 and December 2019 were retrospectively retrieved from the screening log and analysed. The G-ROP screening criteria, consisting of 6 trigger parameters, were applied in infants with complete data. To determine the performance of the G-ROP prediction model for treatment-requiring ROP, sensitivity and specificity were calculated. Complete data were available for 322 infants who were included in the analysis. None of the excluded infants had developed type 1 ROP. By applying the 6 criteria in the G-ROP model, 214 infants were flagged to undergo screening: among these, 14 developed type 1 ROP, 9 developed type 2 ROP, and 43 developed milder stages of ROP. The sensitivity for predicting treatment-requiring ROP was 100% (CI, 0.79-1.00), and the specificity was 41% (CI, 0.35 -0.47). Implementing the novel G-ROP screening criteria would reduce the number of infants entering ROP screening by approximately one third. The overall prevalence of treatment-requiring ROP was low (2.15%). Previously published performance parameters for the G-ROP algorithm were reproducible in this Swiss cohort. Importantly, all treatment-requiring infants were correctly identified. By using these novel criteria, the burden of screening examinations could be significantly reduced.

Sections du résumé

BACKGROUND BACKGROUND
Currently used screening criteria for retinopathy of prematurity (ROP) show high sensitivity for predicting treatment-requiring ROP but low specificity; over 90% of examined infants do not develop ROP that requires treatment (type 1 ROP). A novel weight gain-based prediction model was developed by the G-ROP study group to increase the specificity of the screening criteria and keep the number of ophthalmic examinations as low as possible. This retrospective cohort study aimed to externally validate the G-ROP screening criteria in a Swiss cohort.
METHODS METHODS
Data from 645 preterm infants in ROP screening at Inselspital Bern between January 2015 and December 2019 were retrospectively retrieved from the screening log and analysed. The G-ROP screening criteria, consisting of 6 trigger parameters, were applied in infants with complete data. To determine the performance of the G-ROP prediction model for treatment-requiring ROP, sensitivity and specificity were calculated.
RESULTS RESULTS
Complete data were available for 322 infants who were included in the analysis. None of the excluded infants had developed type 1 ROP. By applying the 6 criteria in the G-ROP model, 214 infants were flagged to undergo screening: among these, 14 developed type 1 ROP, 9 developed type 2 ROP, and 43 developed milder stages of ROP. The sensitivity for predicting treatment-requiring ROP was 100% (CI, 0.79-1.00), and the specificity was 41% (CI, 0.35 -0.47). Implementing the novel G-ROP screening criteria would reduce the number of infants entering ROP screening by approximately one third.
CONCLUSIONS CONCLUSIONS
The overall prevalence of treatment-requiring ROP was low (2.15%). Previously published performance parameters for the G-ROP algorithm were reproducible in this Swiss cohort. Importantly, all treatment-requiring infants were correctly identified. By using these novel criteria, the burden of screening examinations could be significantly reduced.

Identifiants

pubmed: 35012498
doi: 10.1186/s12886-021-02227-4
pii: 10.1186/s12886-021-02227-4
pmc: PMC8751318
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

19

Informations de copyright

© 2022. The Author(s).

Références

Arch Ophthalmol. 2012 Dec;130(12):1560-5
pubmed: 23229697
JAMA Ophthalmol. 2018 Sep 1;136(9):1034-1040
pubmed: 30003216
Pediatrics. 2009 Apr;123(4):e638-45
pubmed: 19289449
Pediatrics. 2005 May;115(5):e518-25
pubmed: 15805336
Ophthalmic Epidemiol. 2017 Feb;24(1):36-47
pubmed: 27996334
Acta Paediatr. 2019 Jun;108(6):1049-1054
pubmed: 30461053
JAMA Ophthalmol. 2018 Apr 1;136(4):409-416
pubmed: 29543944
Am J Ophthalmol. 2019 Sep;205:50-53
pubmed: 30954468
Arch Ophthalmol. 2012 Jun;130(6):720-3
pubmed: 22801831
Eye (Lond). 2012 Mar;26(3):400-6
pubmed: 22193874
JAMA Ophthalmol. 2020 Jan 1;138(1):21-29
pubmed: 31697330
Arch Dis Child. 2017 Sep;102(9):853-857
pubmed: 28465303
Pediatr Res. 2018 Nov;84(5):632-638
pubmed: 30188497
Int Ophthalmol. 2020 Jul;40(7):1647-1652
pubmed: 32200507
JAMA Ophthalmol. 2020 Jan 1;138(1):31-37
pubmed: 31725856
Arch Dis Child Fetal Neonatal Ed. 2021 Mar;106(2):189-193
pubmed: 32989047

Auteurs

Nithursa Vinayahalingam (N)

Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Jane McDougall (J)

Department of Neonatalogy, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Olaf Ahrens (O)

Department of Neonatalogy, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Andreas Ebneter (A)

Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. andreas.ebneter@med.unibe.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH